Anti-ceramide monoclonal antibody 2A2
US9592238B2 · kind B2 · utility
0Cited by
2References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 23, 2013 |
| Grant date | Mar 14, 2017 |
| Priority date | — |
| Expiry date | Aug 23, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.